According to Incyte's latest financial reports the company's current revenue (TTM) is $3.69 B. In 2022 the company made a revenue of $3.39 B an increase over the years 2021 revenue that were of $2.98 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $3.69 B | 8.87% |
2022 | $3.39 B | 13.67% |
2021 | $2.98 B | 11.98% |
2020 | $2.66 B | 23.53% |
2019 | $2.15 B | 14.71% |
2018 | $1.88 B | 22.5% |
2017 | $1.53 B | 38.93% |
2016 | $1.10 B | 46.7% |
2015 | $0.75 B | 47.36% |
2014 | $0.51 B | 44.1% |
2013 | $0.35 B | 19.49% |
2012 | $0.29 B | 214.49% |
2011 | $94.45 M | -44.4% |
2010 | $0.16 B | 1733.53% |
2009 | $9.26 M | 136.35% |
2008 | $3.92 M | -88.62% |
2007 | $34.44 M | 24.58% |
2006 | $27.64 M | 252.29% |
2005 | $7.84 M | -27.13% |
2004 | $10.76 M | -77.13% |
2003 | $47.09 M | -53.66% |
2002 | $0.10 B | -53.66% |
2001 | $0.21 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Novartis NVS | $51.01 B | 1,280.33% | ๐จ๐ญ Switzerland |
Pfizer PFE | $58.49 B | 1,482.86% | ๐บ๐ธ USA |
Eli Lilly LLY | $34.12 B | 823.36% | ๐บ๐ธ USA |
Amgen AMGN | $28.19 B | 662.79% | ๐บ๐ธ USA |
Ligand Pharmaceuticals LGND | $0.13 B | -96.45% | ๐บ๐ธ USA |
Geron GERN | $0.23 M | -99.99% | ๐บ๐ธ USA |
CTI BioPharma
CTIC | $75.76 M | -97.95% | ๐บ๐ธ USA |
AVEO Oncology
AVEO | $94.31 M | -97.45% | ๐บ๐ธ USA |
Ardelyx ARDX | $0.12 B | -96.63% | ๐บ๐ธ USA |